Abstract
We investigated the triazole, amphotericin B, and micafungin susceptibilities of 196 A. fumigatus clinical isolates in Nagasaki, Japan. The percentages of non-wild-type (non-WT) isolates for which MICs of itraconazole, posaconazole, and voriconazole were above the ECV were 7.1%, 2.6%, and 4.1%, respectively. A G54 mutation in cyp51A was detected in 64.2% (9/14 isolates) and 100% (5/5 isolates) of non-WT isolates for itraconazole and posaconazole, respectively. Amphotericin B MICs of ≥2 μg/ml and micafungin minimum effective concentrations (MECs) of ≥16 μg/ml were recorded for two and one isolates, respectively.
MeSH terms
-
Amino Acid Substitution
-
Amphotericin B / administration & dosage
-
Antifungal Agents / administration & dosage*
-
Aspergillosis / drug therapy*
-
Aspergillosis / microbiology
-
Aspergillus fumigatus / drug effects*
-
Aspergillus fumigatus / genetics
-
Aspergillus fumigatus / isolation & purification
-
Cytochrome P-450 Enzyme System / genetics*
-
Drug Resistance, Fungal / drug effects
-
Echinocandins / administration & dosage
-
Female
-
Fungal Proteins / genetics*
-
Humans
-
Itraconazole / administration & dosage
-
Japan
-
Lipopeptides / administration & dosage
-
Male
-
Micafungin
-
Microbial Sensitivity Tests
-
Mutation
-
Pyrimidines / administration & dosage
-
Sequence Analysis, DNA
-
Triazoles / administration & dosage
-
Voriconazole
Substances
-
Antifungal Agents
-
Echinocandins
-
Fungal Proteins
-
Lipopeptides
-
Pyrimidines
-
Triazoles
-
Itraconazole
-
posaconazole
-
Amphotericin B
-
Cytochrome P-450 Enzyme System
-
cytochrome P-450 CYP51A, Aspergillus
-
Voriconazole
-
Micafungin